<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="367033">
  <stage>Registered</stage>
  <submitdate>2/09/2014</submitdate>
  <approvaldate>9/10/2014</approvaldate>
  <actrnumber>ACTRN12614001083684</actrnumber>
  <trial_identification>
    <studytitle>Optimisation of Glycaemic Control in the Setting of Antenatal Corticosteroid Administration in Pregnancies Complicated by Diabetes </studytitle>
    <scientifictitle>Subcutaneous versus Intravenous Insulin Therapy for Glycaemic Control in the Setting of Antenatal Corticosteroid Administration in Pregnancies Complicated by Diabetes</scientifictitle>
    <utrn>U1111-1161-1035</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetes in pregnancy</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Fetal medicine and complications of pregnancy</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Subcutaneous insulin therapy titrated according to maternal blood glucose levels pre- and post-prandial and pre-bed in women with diabetes in pregnancy who receive antenatal corticosteroids for threatened preterm delivery. Subcutaneous insulin administration commenced at initial corticosteroid dose and continued until maternal blood glucose levels normalised, generally 48-72 hours following last corticosteroid dose. </interventions>
    <comparator>Intravenous insulin therapy as per our established protocol titrated to hourly maternal blood glucose levels. Intravenous insulin administration commenced at initial corticosteroid dose and continued until maternal blood glucose levels normalised, generally 48-72 hours following last corticosteroid dose. </comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Optimisation of glycaemic control (maternal blood glucose targets 4.0-8.0mmol/L)</outcome>
      <timepoint>72 hours post-antenatal corticosteroid administration</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of maternal hypoglycaemia (defined as blood glucose level &lt; 4.0 mmol/L) as assessed by bedside glucometer</outcome>
      <timepoint>72 hours post administration of antenatal corticosteroid therapy</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>All women with diabetes in pregnancy (including gestational diabetes and pre-existing diabetes) admitted onto the antenatal or delivery ward at Royal Prince Alfred Hospital who receive emergency or elective antenatal corticosteroids for threatened pre-term delivery.


</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Women with diabetes in pregnancy who received a dose of antenatal corticosteroids at another institution prior to transfer to Royal Prince Alfred Hospital </exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/12/2014</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Royal Prince Alfred Hospital - Camperdown</hospital>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Royal Prince Alfred Hospital Diabetes Centre</primarysponsorname>
    <primarysponsoraddress>Level 6
Royal Prince Alfred Hospital
Missenden Road
Camperdown NSW 2050</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Australasian Diabetes in Pregnancy Society grant (sponsored by NovoNordisk)</fundingname>
      <fundingaddress>145 Macquarie Street 
Sydney NSW 2000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Pregnancy may be complicated by threatened pre-term delivery, which is associated with neonatal respiratory distress syndrome. Antenatal corticosteroids reduce the incidence of neonatal respiratory distress syndrome in preterm delivery but cause acute severe maternal hyperglycaemia in pregnancies complicated by diabetes. Data is limited on the blood glucose profile following corticosteroid administration and guidelines to control hyperglycaemia are lacking. Intravenous (IV) insulin infusions may be utilised but are labour intensive and require significant expertise. 

This prospective interventional study seeks to prospectively validate in-patient management principles utilising a supplementary subcutaneous (SC) insulin regimen in comparison to IV insulin infusion titrated to predicted maternal hyperglycaemia to reduce hyperglycaemia in diabetic pregnancies.

</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>SLHD Ethics Review Committee (RPAH Zone) / Animal Welfare Committee</ethicname>
      <ethicaddress>Level 2
Medical Centre
100 Carillon Ave
Camperdown NSW 2050</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>8/09/2014</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Arianne Sweeting</name>
      <address>Endocrinology &amp; Metabolism Unit
Level 6
Missenden Road
Royal Prince Alfred Hospital
Camperdown NSW 2050</address>
      <phone>+61 2 9515 7226</phone>
      <fax />
      <email>Arianne.Sweeting@sswahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Arianne Sweeting</name>
      <address>Endocrinology &amp; Metabolism Unit
Level 6
Missenden Road
Royal Prince Alfred Hospital
Camperdown NSW 2050</address>
      <phone>+61 2 9515 7226</phone>
      <fax />
      <email>Arianne.Sweeting@sswahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Arianne Sweeting</name>
      <address>Endocrinology &amp; Metabolism Unit
Level 6
Missenden Road
Royal Prince Alfred Hospital
Camperdown NSW 2050</address>
      <phone>+61 2 9515 7226</phone>
      <fax />
      <email>Arianne.Sweeting@sswahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>